MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4
Background

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.

In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.

Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite), Hypothyroidism, Localized Adiposity, Myxedema coma, Euthyroid Goitre, Thyrotropin dependent Well-Differentiated Thyroid Cancer

The Effect of Levothyroxine on Arterial Stiffness and Lipid Profile in Patients With Subclinical Hypothyroidism

Not Applicable
Completed
Conditions
Subclinical Hypothyroidism
First Posted Date
2007-07-09
Last Posted Date
2007-07-09
Lead Sponsor
Assaf-Harofeh Medical Center
Target Recruit Count
34
Registration Number
NCT00498238

Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

Not Applicable
Terminated
Conditions
Hypothyroidism
Brain Tumor
Interventions
First Posted Date
2007-06-20
Last Posted Date
2013-06-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
12
Registration Number
NCT00488644
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Generic vs. Name-Brand Levothyroxine

Not Applicable
Completed
Conditions
Congenital Hypothyroidism
Hypothyroidism
Interventions
First Posted Date
2006-11-23
Last Posted Date
2018-02-23
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
34
Registration Number
NCT00403390
Locations
🇺🇸

Children's Hospital Boston, Boston, Massachusetts, United States

Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy

Phase 3
Completed
Conditions
Pregnancy
Subclinical Hypothyroidism
Hypothyroxinemia
Interventions
First Posted Date
2006-10-16
Last Posted Date
2019-02-21
Lead Sponsor
The George Washington University Biostatistics Center
Target Recruit Count
1203
Registration Number
NCT00388297
Locations
🇺🇸

University of Utah Medical Center, Salt Lake City, Utah, United States

🇺🇸

Oregon Health & Sciences University, Portland, Oregon, United States

🇺🇸

Wayne State University, Detroit, Michigan, United States

and more 11 locations

Thyroid Hormone Dose Adjustment in Pregnancy

Not Applicable
Completed
Conditions
Pregnancy
Hypothyroidism
Interventions
First Posted Date
2005-10-03
Last Posted Date
2016-12-23
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
48
Registration Number
NCT00230802
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Thyroxine Titration Study

Phase 4
Conditions
Hypothyroidism
First Posted Date
2005-05-25
Last Posted Date
2005-06-24
Lead Sponsor
Sir Charles Gairdner Hospital
Target Recruit Count
55
Registration Number
NCT00111735
Locations
🇦🇺

Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath